盘后交易 19:00 (美东)237.600USD+0.320+0.14%关键数据
242.420今开
248.750最高
376.91K成交量
亏损市盈率 TTM
410.19市盈率动
--股息TTM
0.64%换手率
242.480昨收
207.410最低
90.46M成交额
亏损市盈率静
19.53市净率
0.00%股息率 TTM
-20.36%ROA
248.75052周最高
113.28量比
-146.37M净利润
58.98M总股本
-3.3024每股收益TTM
0.86Beta
-26.39%ROE
80.90552周最低
17.05%振幅
85.23%毛利率
14.01B总市值
6.29回报/风险
3.26%风险率

即将为您带来更多新闻,敬请期待。。。
Glaukos Corp评分
0.34与上次评分对比预测8.71
财务诊断7.89
技术分析6.28
公司估值9.71
机构认同度10.00
风险评估7.61
分析师评级
买入评级
220.417目标均价
+21.49%涨幅空间
Glaukos Corp 最新财报电话会记录
Glaukos (GKOS) 2026年第三季度业绩电话会:上调业绩指引,2027年营收目标为10亿美元
在Epioxa和iDose TR的推动下,Glaukos 2026财年第三季度销售额增长58%至2.11亿美元。管理层上调了2026财年业绩指引,并提出了10亿美元的2027财年业绩展望。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
Glaukos Corp 简介
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
行业医疗设备与耗材
公司代码GKOS
员工数量995
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| BlackRock Institutional Trust Company, N.A. | 13.75% |
|---|
| PRIMECAP Management Company | 5.74% |
|---|
| Vanguard Portfolio Management, LLC | 5.46% |
|---|
| Janus Henderson Investors | 5.14% |
|---|
| 股东类型 | 占比 |
|---|
| Investment Advisor | 50.27% |
|---|
| Investment Advisor/Hedge Fund | 31.24% |
|---|
| Hedge Fund | 11.62% |
|---|
| Individual Investor | 3.59% |
|---|
常见问题
Glaukos Corp(GKOS)的当前股价是多少?
Glaukos Corp(GKOS)的当前股价是 242.48。
Glaukos Corp股票的52周最高点是多少?
Glaukos Corp股票的52周最高点是191.62。
Glaukos Corp股票的52周最低点是多少?
Glaukos Corp股票的52周最低点是80.91。
现在Glaukos Corp(GKOS)的股票是买入、持有还是卖出?
根据分析师评级,Glaukos Corp(GKOS)的总体评级为买入,目标价格为220.42。
Glaukos Corp(GKOS)股票的每股收益(EPS TTM)是多少
Glaukos Corp(GKOS)股票的每股收益(EPS TTM)是-3.30。